


Curriculum Vitae

	Name (First Name, Middle Name Last Name)	Qian Cao
	Position	Professor of Medicine, Chief of Gastroenterology Department, Vice director of IBD center
	Affiliation	Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
	Country	China
	Major Field	Gastroenterology, IBD

Education Background

GI Fellow 2003.9~ 2008.8, Gastroenterology Department, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Ph.D 2002.9~2005.6, Zhejiang University, School of Medicine
 2003.4~2004.3 Gibson Laboratories, Radcliffe Infirmary, Nuffield Department of Clinical Medicine, University of Oxford, UK
M.D 1992.9~1997.6, Zhongshan Medical University

Professional Experience

Prof. Qian Cao is the chief of gastroenterology department at Sir Run Run Shaw Hospital, school of medicine, Zhejiang University. She is the key member of IBD group at Chinese Society of Digestive Disease, CMA and the leader of IBD group of Zhejiang Society of Digestive Disease, ZJMA. She is also a member of Clinical research committee of AOCC. Prof. Cao has more than 20 years of clinical experience in the field of IBD. Her research interest lies in immunomodulators and novel biologic therapy for patients with IBD, as well as IBD patient management and long-term clinical outcomes. Dr. Cao lead a research team which focuses on epidemiological study, health economic research on IBD patients, as well as intestinal immunity, genetic susceptibility genes of inflammatory bowel disease in Chinese population.

Professional Organizations

- Chief** Inflammatory bowel disease subspecialty group, Digestive Disease Branch, Zhejiang Medical Association (2018)
- Deputy Chief** Decontamination group, Digestive Disease Branch, Zhejiang Medical Association (2019)
- Deputy Chief** Enteroscopy and capsule endoscopy, Digestive Disease Branch, Zhejiang Medical Association (2019)
- Member** Standing Committee of Digestive Disease Branch of Zhejiang Medical Association (2013)
- Member** Standing Committee of internal medicine branch of Zhejiang Medical Association (2018)
- Consultant** Inflammatory bowel disease group, Digestive society of Chinese Medical Association (2018)
- Member** AOCC clinical research committee (2017)
- Vice Chairman** Digestive endoscopy branch, Zhejiang Medical Association (2019)

Scientific Publication

1. Huang, L, Mao, X, Li, Y, Liu, D, Fan, K, Liu, R, Wu, T, Wang, H, Zhang, Y, Yang, B, Ye, C, Zhong, J, Chai, R, **Cao, Q**, & Jin, J. Multiomics analyses reveal a critical role of selenium in controlling T cell differentiation in Crohn's disease. *Immunity*. 2021;54(8):1728-1744.
2. Ye L, Chapman TP, Wen Z, Lin L, Qiu Y, Liu Z, Ran Z, Qian J, Wu K, Gao X, Hu P, Chen M, Travis SPL, **Cao Q**; Chinese IBD Elite Union. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. *Aliment Pharmacol Ther*. 2021 Feb;53(3):390-399. doi: 10.1111/apt.16130. Epub 2020 Dec 12. PMID: 33314259; PMCID: PMC7839545.
3. Liu R, Wang M, Zhang L, Zhou W, Huang Y, Guo H, Gu Y, Chen Y, Li Y, Chen C, Wang Y, Rong L, Li J, Xu J, **Cao Q**, Jiang Z. The clinicopathologic features of chronic active Epstein-Barr virus infective enteritis. *Mod Pathol*. 2019 Mar;32(3):387-395. doi: 10.1038/s41379-018-0144-1. Epub 2018 Oct 8. PMID: 30297882.

4. Xiao P, Zhang H, Zhang Y, Zheng M, Liu R, Zhao Y, Zhang X, Cheng H, **Cao Q**, Ke Y. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10. *J Exp Med*. 2019 Feb 4;216(2):337-349. doi: 10.1084/jem.20181198. Epub 2019 Jan 4. PMID: 30610104; PMCID: PMC6363431.
5. Zhang Y, Liu RB, **Cao Q**, Fan KQ, Huang LJ, Yu JS, Gao ZJ, Huang T, Zhong JY, Mao XT, Wang F, Xiao P, Zhao Y, Feng XH, Li YY, Jin J. USP16-mediated deubiquitination of calcineurin A controls peripheral T cell maintenance. *J Clin Invest*. 2019 May 28;129(7):2856-2871. doi: 10.1172/JCI123801. PMID: 31135381; PMCID: PMC6597231.
6. Xiao P, Guo Y, Zhang H, Zhang X, Cheng H, **Cao Q**, Ke Y. Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN- γ production in tumor microenvironment. *Oncogene*. 2018 Sep;37(37):5088-5100. doi: 10.1038/s41388-018-0337-6. Epub 2018 May 24. PMID: 29795405.